Understanding the mechanisms that control stress-induced apoptosis is critical to explain how tumours respond to treatment, as cancer cells frequently escape drug toxicity by regulating stress response through heat shock protein (HSP) expression. The overexpression of Hsp72, in particular, results in increased incidence of cell transformation, and correlates with poor prognosis in a wide range of cancers. We have shown that Hsp72 assists folding of oncogenic NPM --ALK kinase in anaplastic large-cell lymphomas (ALCLs), but its role in the maintenance of the malignant phenotype remains uncertain. Therefore, we assessed Hsp72 expression in ALCLs, investigating more in detail the mechanisms that regulate its status and activity. We found that Hsp72 is unique among the HSPs involved in tumourigenesis to be overexpressed in ALK þ tumours and cell lines and to be induced by stress. Different from other HSPs, Hsp72 prevents cell injury, Bax activation and death by apoptosis in ALK þ cells, acting both upstream and downstream of mitochondria. Conversely, Hsp72 is underexpressed in ALK À ALCL cells, and it is unable to protect cells from apoptosis under stress. Moreover, when Hsp72 expression is reduced following NPM --ALK inhibition, lymphoma cells undergo apoptosis, demonstrating the importance of Hsp72 in regulating ALCL stress response and drug sensitivity.
INTRODUCTION
Heat shock proteins (HSPs) are molecular chaperones responsible for folding newly synthesized polypeptides under physiological conditions and misfolded proteins under stress. They function by preventing unwanted protein aggregation and degradation, and preserve cell growth and division from environmental insults. In cancer, increased HSP expression reflects the harmful growth conditions that tumour cells come across, including hypoxia, inflammatory cytokines, irradiation and oxidative stress, and HSPs represent key players of many signalling pathways that help cancer cells to cope with the stress of their oncogenic state and that induced by a wide range of pharmacological agents. 1, 2 Among them, heat shock 72 kDa protein (Hsp72) is critical for growth and survival of transformed cells, because it serves as molecular chaperone that assists folding of nascent polypeptides and the intracellular localization of native proteins, as well as it acts to protect cells to repeat exposure of noxious stimuli that would otherwise cause lethal molecular damages. Hsp72 is frequently overexpressed in several tumour types, whereas in normal cells its expression is limited by the transcriptional activity of HSF1 (heat shock factor 1) during cell stress response. 3 --5 Hsp72 provides a survival advantage through the inhibition of several components of the apoptotic pathway, including DNA-damaging factors, proapoptotic Bcl-2 family member proteins and stress protein kinases, but whether cancer cells survive because of the constitutive expression of Hsp72 or the ability to induce it when they rapidly adapt to stressful conditions remains uncertain.
We and others have demonstrated the critical role of HSPs in regulating growth and invasiveness of anaplastic large-cell lymphomas (ALCLs), but the involvement of HSPs in ALCL cell survival has never been investigated. 6, 7 ALCLs are high-grade non-Hodgkin lymphomas that are characterized by rearrangements of the ALK (anaplastic lymphoma kinase) gene on chromosome 2. The chromosomal translocation t(2;5)(p23;q35) that originates the NPM --ALK (nucleophosmin --anaplastic lymphoma kinase) fusion protein kinase is the most frequent rearrangement observed in ALCL patients, and NPM --ALK is a main determinant for tumour development. 8 Essential for proper NPM --ALK activity are Hsp90 and Hsp72, as impairment of their chaperoning activity affects NPM --ALK folding, and leads to ALCL cell growth inhibition following NPM --ALK ubiquitination and proteasomal degradation. NPM --ALK is functionally inactive when ubiquitinated, and the maintenance of such a posttranslational state leads rapidly to cell cycle arrest and apoptosis. 9 Prolonged inhibition of the 26S proteasome is therefore an effective therapeutic strategy against ALCLs, although a compensatory heat shock response occurs as side effect of treatment and somehow limits drug effectiveness. In this study we sought to examine the constitutive and inducible expression of Hsp72 in ALCL cells, to better define its role under normal and stressful conditions caused by heat shock or proteasome inhibition. The data presented here demonstrate that Hsp72 is overexpressed in ALK þ tumours and cell lines, and it plays a role in cell resistance to injury caused by hyperthermia or drug treatment. We provided evidence that Hsp72-mediated cytoprotection is part of the NPM --ALK survival signalling of ALCL cells, as when induced, Hsp72 protects mitochondria from damages and cells from apoptosis, whereas when Hsp72 is downregulated in response to NPM --ALK inhibition, lymphoma cells do not withstand proteotoxic stress and rapidly undergo caspase-dependent cell death.
MATERIALS AND METHODS

Patients, cell lines and treatments
Lymph node biopsies were obtained at diagnosis from patients with ALCLs at the Department of Pathology, University of Padova, and at the Department of Pathology of Toulouse University Medical Center (France), after informed consent. The study group included 31 ALCLs, whose diagnosis was based on criteria specified by the 2008 WHO (World Health Organization) classification. All the ALCLs expressed CD30, 21 were positive to ALK staining, whereas 10 were ALK À systemic ALCLs. The median age of ALK þ patients was 10.2 years compared with 9.7 years for ALK À patients.
The study was carried out in accordance with both local ethical guidelines and the ethical guidelines of the studies on human specimens. Informed consent for biological studies was obtained from patients or guardians of each patient enroled in the study. For the in vitro studies, four ALK þ ALCL cell lines carrying the t(2;5) translocation (KARPAS-229, SU-DHL-1, SUP-M2 and SR-786) and one ALK À cell line (FE-PD) were used. Cells were maintained in standard growth conditions as described. 6 Heat shock was performed in a water bath (42.0 --43.0 1C) for 30 min, and after that the cells were placed at 37 1C to recover for the indicated times. To induce apoptosis, the cells were incubated for the same time intervals in the presence of the proteasome inhibitor bortezomib (BZ), whereas when treatments were combined, exposure to BZ was preceded by a 30-min heat shock. Cells were also treated with the ALK inhibitor whi-p154 (4-(3 0 -bromo-4 0 -hydroxylphenyl)-amino-6,7-dimethoxyquinazoline), in the presence or absence of BZ as indicated.
Real-time PCR analysis ALCL cells were lysed and total RNA was isolated and purified according to our previously described protocols. 10 Complementary DNA was reverse transcribed from 1 mg of total RNA, using SuperScript II reverse transcriptase (Invitrogen, Life Technology Corp., Carlsbad, CA, USA) and random hexamers. Primers and probe sequences for heat shock cognate 70 kDa protein (Hsc70), Hsp72, Hsp40, Hsp90a and Hsp90b RNA were purchased from Applied Biosystems (TaqMan Gene Expression Assays, Applied Biosystems, Foster City, CA, USA), and real-time quantitative PCR was performed with TaqMan universal PCR Master Mix (Applied Biosystems). 11 All samples were run in triplicates, and target transcripts were normalized to endogenous 18S or GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA as required (Applied Biosystems). Total RNA was isolated from 21 ALK þ ALCLs, 10 ALK À and 8 reactive lymph nodes, and from ALCL cell lines.
Gene expression profiling and data analysis
Total RNA of ALCL cell lines was isolated using Trizol Reagent (Invitrogen, Life Technology Corp.) from 5 Â 10 6 cells, and gene expression profiles were generated starting from 5 mg of total RNA as previously described. 12 Gene expression profiles were determined by Affymetrix Microarray Suite 5.0 (MAS 5.0) software (Affymetrix, Santa Clara, CA, USA), using the Global Scaling option. Washing and staining of genechip arrays were performed in 450/250 Fluidics Station, and scanned with GeneChip Scanner 3000 (Affymetrix) to acquire images. MAS 5.0-normalized gene expression profiles were used in the analyses. Then, selecting ALK-negative FE-PD as reference line, we calculated the log-transformed expression ratio of each cell line relative to the reference. Unsupervised clustering was performed using Euclidean distance and complete-linkage method. To identify genes differentially expressed between ALK þ and ALK À cells, we performed Significance Analysis of Microarray (SAM) test (false discovery rate of o1.0E --06).
Subcellular fractionation, immunoprecipitation and western blot
Cells in log-phase growth were collected and lysed in Triton X-100 nonionic sample buffer, and western blot analysis was performed using standard methods. The lysates were clarified by high-speed centrifugation and analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis before transferring onto nitrocellulose membranes. Antibodies used to probe the membranes were specific for Hsp72, Hsc70, Hsp90, Hsp40, Hsp60, HSF1 (Assay Design, Ann Arbor, MI, USA); tubulin (SIGMA-Aldrich, Saint Louis, MO, USA); actin, HDCA1, STAT3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); cytochrome c (BD Biosciences, San Jose, CA, USA); Bax (Upstate Biotechnology, Lake Placid, NY, USA); caspase 3 (Axxora Life Science, San Diego, CA, USA); NPM --ALK (Invitrogen, Life Technology Corp.,); NPM --ALKY664, poly(ADP-ribose)polymerase (PARP) and STAT3Y705 (Cell Signalling Technology, Danvers, MA, USA). Immunoprecipitation was performed as described previously, 6 with the specific primary antibodies indicated. To separate cytosolic proteins from membrane-bound mitochondrial fractions, lysates were obtained by resuspending ALCL cells into digitonin-lysis buffer, before digesting the enriched mitochondrial pellets as described. 9 To isolate nuclei, treated and untreated cells were lysed in 2% NP-40 Hypotonic buffer (10 mM KCl), and cell pellets containing intact nuclei were disrupted mechanically before recovering the nuclear content by high-speed centrifugation. Proteins were analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting. To prepare cell extracts and measure the in vitro caspase activity, preheated ALCL cells were lysed into cytoplasmic extraction buffer (CEB; 50 mM PIPES, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM DTT and 0.05% digitonin) and incubated on ice for 15 min. Activation of endogenous caspases was induced by addition of 1 mM ATP (Invitrogen) and 10 mM horse-heart cytochrome c (SIGMA-Aldrich) to cell extracts (200 --300 mg protein equivalent) in a total volume of 100 ml, and incubation at 37 1C for 1 and 2 h. Protein aliquots were analysed by western blotting, probing membranes for caspase-3, Hsp72 and PARP.
Fluorescence microscopy Our immunofluorescence assays were described previously. 10 Fixed cells were incubated with the indicated primary antibodies, and thereafter with Alexa Fluor-labelled secondary antibodies (Life Technology Corp., Carlsbad, CA, USA). Images were captured with Leica DMBL microscope (40 Â NA or 63 Â /0.75 NA) equipped with Leica DC 300F digital camera, and prepared for reproduction with Leica IM1000 software (Leica Microsystem Ltd, Wetzlar, Germany).
Assessment of apoptosis
To measure drug-induced apoptosis, ALCL cells were treated as indicated in figures and stained with Annexin V/fluorescein isothiocyanate before flow cytometry analysis. Briefly, cells were harvested, washed with temperate phosphate-buffered saline, before staining with Annexin V (AV)/propidium iodide (PI) in Annexin-binding buffer (10 mM HEPES, pH 7.4; 140 mM NaOH; 2.5 mM CaCl 2 ; Immunostep S.L., Salamanca, Spain). FACSCalibur flow cytometer (BD Biosciences) was used to analyse early apoptotic (AV þ /PI À ) and late (AV þ /PI þ ) apoptotic cells.
Tissue microarray construction and immunohistochemistry
Tissue microarray was constructed with formalin-fixed, paraffin-embedded ALCL specimens described above. Lymphoma samples and nonmalignant specimens were selected by local pathologists. Representative tissue areas for Tissue Micro Array were identified on the histological slides, and three cores per tumour sample were used. Tissue cores were arrayed into a recipient block using a tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA). Sections were stained with antibodies against Hsc70 (Santa Cruz Biotechnology) and Hsp72 (Assay Design) after deparaffinization, rehydration and antigen retrieval. Detection of the immunoreaction was performed using peroxidase-based EnVision kit (Dako Denmark A/S, Glostrup, Denmark). For counterstaining cells haematoxylin was used. Cases were considered positive when at least 20% of the neoplastic cells showed unequivocal staining for either Hsc70 or Hsp72, with intensity varying from weak to strongly positive.
RESULTS
Hsp72 is overexpressed in ALK-positive ALCLs
Because high Hsp72 expression correlates with poor prognosis in several cancer types, we decided to assess Hsp72 transcript levels in a series of ALK-positive (ALK-pos, n ¼ 21) and ALK-negative (ALK-neg, n ¼ 10) ALCLs, and in reactive lymph nodes (Controls, n ¼ (Figure 1a ). To confirm these findings, we quantified protein expression on a series of ALK þ specimens (n ¼ 18) and control lymph nodes (n ¼ 8) for which whole cell lysates were available. Consistent with real-time quantitative PCR analysis, ALK þ samples expressed much more Hsp72 protein than normal cells (Lymph, P ¼ 0.006), whereas differences in the expression of other stress-related proteins, including Hsc70, Hsp90, Hsp40 and HSF1, were modest or not significant (Figure 1b) . Furthermore, when tumour biopsies (21 ALK þ and 6 ALK À ALCLs) were assessed for protein expression by tissue microarray, Hsc70 was found in both ALK þ and ALK À ALCLs, whereas Hsp72 was expressed only in ALK Table) . Staining intensity was graded as 0 (absent), 1 (weak), 2 (moderate) and 3 (strong), after capturing images with HC/PL Fluotar 40 Â /0.85 numerical aperture objective lens. Representative areas of selected ALK þ and ALK À tumour cores stained for Hsc70 and Hsp72 are shown aside. types of cancer. During stress, Hsp72 expression is induced by HSF1 DNA binding and transcriptional activity, whereas in normal conditions transcription factors other than HSF1, such as STAT3 and NF-IL6, modulate Hsp72 synthesis. Inhibitors of the proteasome have been studied for their anticancer activity, but although they are well tolerated, a major side effect that limits their use in patients is the induction of Hsp72. Therefore, Hsp72 expression was induced by exposing cells to equal toxic concentrations of proteasome inhibitor BZ, 9 or after thermotolerant HS, and steadystate analysis of Hsp72 and PARP proteins were measured during stress response (Figure 3a) . Exposure to 43 1C for 30 min and 100 nM BZ were optimal conditions to stress ALK þ cells, whereas exposure to 42 1C for 30 min and 10 nM BZ were the conditions selected to treat the more sensitive ALK À FE-PD cells. Under these settings, ALK þ cells (KARPAS-299 and SU-DHL-1) responded to stress by inducing Hsp72, whereas ALK À FE-PD cells were unable to stimulate Hsp72 expression, as the slight increase observed after BZ treatment was because of altered turnover of mature Hsp72 chaperone protein rather than to its enhanced synthesis (Figure 3b ). In these conditions, steady state of cognate Hsc70 protein did not change, suggesting that, unlike Hsp72, Hsc70 is not a stress-inducible chaperone protein in ALCL cells. These results were supported by the analysis of HSF1 expression and subcellular localization, which demonstrated that nuclear accumulation of HSF1 in ALK þ cells exposed to BZ proteasome inhibitor correlated with HSF1 phosphorylation and activation (Figure 3c, p-HSF1) , and with increased Hsp72 protein and mRNA levels (Figures 3c and d, respectively) . Under these conditions, neither phosphorylation of HSF1 nor Hsp72 expression was induced in ALK À FE-PD cells (Figures 3c and d) . HSF1 exists in a repressed cytoplasmic state when associated with Hsp90, whereas it is inhibited by Hsp72 during stress recovery. 13, 14 Therefore, to support stress-induced activation of HSF1 and demonstrate its dynamic regulation by Hsp72, we analysed HSF1/Hsp72 complex formation in ALCL cells, before and after heat shock or drug treatment. As shown in Figure 3e , HSF1 bound constitutively Hsp72 only in ALK þ cells (KARPAS-299 and SU-DHL-1), and such a complex increased on stress. In contrast, HSF1 did not associate with Hsc70, suggesting that cognate Hsc70 protein does not modulate HSF1 activity in ALCL cells. Consistent with these results, microscopic analysis of HSF1 and Hsp72 intracellular localization was carried out in ALK þ and ALK À ALCL cell lines, showing that the two proteins distributed differently after short exposure to BZ (Figures 3f, 4h, arrows) , whereas they exhibited a similar subcellular distribution pattern after prolonged stress (24 h) in cells where their mutual interaction was previously observed (Figure 3f , KARPAS-299). Of note, when the cells were pretreated with NPM --ALK inhibitor whi-p154, BZ-mediated accumulation of HSF1 and Hsp72 was blocked, and apoptosis was induced (Figures 3g and h, respectively) .
Role of Hsp72 in ALCL cell survival Because Hsp72 protects transformed cells from apoptosis by acting as a natural inhibitor of several stress kinases, as well as it prevents damages to mitochondria through the modulation of the activity of various pro-and anti-apoptotic proteins, 15 we examined Hsp72 antiapoptotic activity in ALCL cells by assessing cytosolic release of cytochrome c from mitochondria and Bax activation after both mild heat shock preconditioning and exposure to BZ proteasome inhibitor. Consistent with our previous results, high Hsp72 expression levels in SU-DHL-1 cells correlated with reduced sensitivity to stress-induced apoptosis, as demonstrated by limited processing of caspase 3 in these cells, retention of Bax in the cytoplasm and inhibition of cytochrome c release from mitochondria after treatment ( Figure 4A ). Low-Hsp72-expressing FE-PD cells, in contrast, were unable to prevent accumulation of Bax in the membrane-bound fraction and subsequent release of cytochrome c into the cytosol, and activation of caspase 3 was observed even under stressful conditions that were not efficacious in SU-DHL-1 cells ( Figure 4A , 10 nM BZ, Bort.). These results were validated by using a conformation-specific anti-Bax (6A7) antibody, which demonstrated that Bax exhibited a sparse cytosolic distribution in unstressed SU-DHL-1 and FE-PD cells, whereas it accumulated in a more punctuate distribution pattern typical of its mitochondrial insertion in drug-treated ALK À FE-PD cells undergoing apoptosis (FE-PD, Figure 4B ). Failure of active Bax to translocate into mitochondria of SU-DHL-1 cells correlated with inhibitory binding of Hsp72 to Bax, which was not observed in ALK À FE-PD cells when either of the proteins were immunoprecipitated ( Figure 4C , upper and middle panels, respectively). However, to test the ability of cytochrome c to activate caspase 3, we used an in vitro apoptosis system bypassing Bax activation and mitochondrial injury. Extracts prepared from control (37 1C) and heat-shocked cells (42 --43 1C) were incubated with purified cytochrome c and ATP, and apoptosis was determined by monitoring time-dependent processing and activity of caspase 3 ( Figures 4D and E, respectively) . Western blot analysis revealed that caspase 3 was processed to form active caspase 3 subunits ( Figure 4D , 17 and 19 kDa) after the addition of cytochrome c in both uninduced SU-DHL-1 and FE-PD cells, and this corresponded with the time at which PARP cleavage occurred ( Figure 4E ). Heatinduced Hsp72 expression, instead, inhibited the activity of mature caspase 3 enzyme in the presence of exogenous cytochrome c (Figure 4e , PARP cleavage), but it did not prevented prior processing of the immature enzyme ( Figure 4D, Casp.3 ). This was evident in thermotolerant SU-DHL-1 cells but not in ALK À FE-PD cells, where the modest induction of Hsp72 after heat shock was not sufficient to block caspase-3-dependent cleavage of PARP, neither before nor after the addition of exogenous cytochrome c ( Figures 4D and E, respectively) . Therefore, cells with elevated constitutive expression of Hsp72, like SU-DHL-1, resisted to apoptosis in response to stress as a consequence of reduced caspase-3 activity and Hsp72 ability to prevent upstream key signalling steps leading to caspase 3 activation.
DISCUSSION
As chemotherapy has emerged as the most efficacious modality to treat cancer, investigating how tumour cells cope with stress and survive drug-induced apoptosis is critical to understand how resistance develops in patients. HSPs are regulators of protein homeostasis and cell survival under both stressful and nonstressful conditions, and their overexpression clinically correlates with resistance to therapy and poor prognosis. 16, 17 Cancer evolves through random mutations and epigenetic changes of selected cells, which survive and proliferate under conditions that would be normally lethal. A minority of such mutations drives cancer phenotype and identifies a state of dependency known as 'oncogene addiction', whereas the vast majority of them are non-driving 'passenger' mutations. 18 ALCL is a good example of oncogene-addicted cancer, as ALCL cells rely on the aberrant expression and signalling of NPM --ALK kinase to proliferate, disseminate and survive apoptosis.
19 --22 NPM --ALK, like other deregulated tyrosine kinases, activates classical survival signalling pathways, such as those regulated by STAT3, AKT and RAS, and tumours harbouring amplifications, translocation or point mutations of the ALK gene result in widespread apoptosis if ALK is inhibited or silenced. 23 --25 Nonetheless, cancer cells may display dependence on the normal cellular functions of genes that act in oncogenic pathways in a rate-limiting manner although they are not oncogenes per se, and this is known as 'nononcogene addiction'. 26 HSPs represent a clear example of nononcogene addiction genes, based on the fact that they are frequently overexpressed in tumours and their selective inhibition readily induces apoptosis. House-keeping functions of HSPs include chaperone activity, folding and protection against protein misfolding, 27,28 whereas critical functions of HSP that allow growth and survival of tumour cells consist of the ability to maintain the transformed phenotype and to prevent stress-induced apoptosis. 29, 30 Proliferating tumour cells need higher levels of HSPs to maintain protein quality control, and in turn HSP overexpression is sustained by the oncogenic state of tumours. 31 --34 Although stress-inducible HSPs are barely detectable in normal cells, their expression is enhanced during oncogenesis, as they serve to maintain the cancer phenotype against stressor conditions such as those deriving from aneuploidy, copy number variation and transcriptional alterations. HSPs may be therefore considered potential drug targets given their widespread roles in both nonstress and stressful conditions, and Hsp72 has gathered significant attention over the past few years as the importance of its modulatory function has been demonstrated in a wide range of pathophysiological states, including cancer. Hsp72, in fact, broadly shapes cell homeostasis by affecting protein expression and turnover, and when this occurs upon stress induction, it provides survival advantages by binding and inhibiting multiple components of the caspase-dependent and caspase-independent apoptotic pathways. The fact that the cytotoxic effects of Hsp72 downmodulation are so important for the survival of transformed cells is consistent with the notion that tumours are particularly dependent on Hsp72 expression and activity, because their constitutive stressed phenotype requires the continuous cytoprotective action of this chaperone.
The main aim of this study was to examine Hsp72 expression and activity in ALCL tumours and cell lines, in order to determine whether Hsp72 is acting during stress response and is capable of inhibiting caspase-dependent apoptosis. This study provides evidence that cancer cells expressing the oncogenic NPM --ALK kinase contain elevated levels of Hsp72, and are more resistant to stress conditions that lead to apoptosis. In particular, ALK þ cells cope with hyperthermia and cytotoxicity induced by proteotoxic drugs like proteasome inhibitor BZ by inducing and maintaining high levels of antiapoptotic Hsp72 protein, which in turn limits cell damages, blunts death signals and prevents the execution of apoptosis. Synthesis and expression of Hsp72 in ALCL cells appears to be mediated by NPM --ALK, which under stressful conditions is triggered by HSF1 transcriptional activity, through a step-wise process that includes HSF1 nuclear relocalization, acquisition of a DNA-binding competent state and stress-inducible phosphorylation. Inhibition of NPM --ALK reduces Hsp72 expression at both mRNA and protein levels, and enhances stressinduced apoptosis. In comparison, in the presence of NPM --ALK, stress-induced Hsp72 provides protection against heat-and druginduced apoptosis at multiple levels, by affecting both upstream signalling and downstream effector events. 35 --37 Data supporting this conclusion come from the observation that in cells expressing oncogenic NPM --ALK kinase, Hsp72 prevents stress-induced activation of proapoptotic Bax upstream of mitochondrial injury, inhibits release of cytochrome c from the mitochondria and limits downstream caspase 3 activity. 38, 39 Indeed, we provided evidence that transiently elevated expression of Hsp72 in response to stress binds and prevents Bax activation and relocalization from the cytosol to mitochondria. This maintains mitochondria stability against heat shock and drug-induced injury, and inhibits activation of sensor effector caspase 3 protein. By doing this, Hsp72 chaperone inhibits apoptosis upstream of the cellular commitment to death, which is either at or upstream of the mitochondria. Indeed, when Hsp72 expression is reduced following NPM --ALK inhibition, drug-induced apoptosis increases in ALK þ ALCL cells, suggesting that resistance in these cells is at least in part ascribed to the survival activity of Hsp72.
In summary, our results show that Hsp72 is overexpressed in NPM --ALK-positive ALCL tumours and cell lines, where it may exert its antiapoptotic activity under stressful conditions that promote caspase-dependent cell death. In these conditions, Hsp72 intervenes both upstream and downstream of mitochondria injury, and it may in part account for the ability of NPM --ALK to affect response to stress-induced apoptosis. The identification of Hsp72 as a new player in the protein quality control and survival of ALCL cells gives new insights into the aetiology of this type of cancer, and it may have important clinical implications for the treatment.
